Immunoglobulin Y (abbreviated as IgY) is a type of immunoglobulin which is the major antibody in bird, reptile, and lungfish blood. It is also found in high concentrations in chicken egg yolk. As with the other immunoglobulins, IgY is a class of proteins which are formed by the immune system in reaction to certain foreign substances, and specifically recognize them.
IgY antibodies have a different structure from IgG, particularly in the Fc and hinge regions. The affinity maturation process of IgY is also different from IgG. These biological features underlie IgY's competitive advantages over IgG. Shown in the four panels are several comparisons between IgY and IgG.
IgY is a hen egg polyclonal antibody. Hen eggs contain more than 450 separate antibodies and when consumed, are not rejected by the human immune system.
North America is the largest consumption place, with a consumption market share nearly 37.5% in 2017; Europe is the second largest consumption place with the consumption market share of 30% in 2017.
The global IGY Polyclonal Antibodies market is valued at 4 million US$ in 2018 and will reach 12 million US$ by the end of 2025, growing at a CAGR of 13.4% during 2019-2025. The objectives of this study are to define, segment, and project the size of the IGY Polyclonal Antibodies market based on company, product type, end user and key regions.
This report studies the global market size of IGY Polyclonal Antibodies in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of IGY Polyclonal Antibodies in these regions.
This research report categorizes the global IGY Polyclonal Antibodies market by top players/brands, region, type and end user. This report also studies the global IGY Polyclonal Antibodies market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
IGY Life Sciences
Market size by Product
Market size by End User
Market size by Region
Central & South America
Rest of Central & South America
Middle East & Africa
The study objectives of this report are:
To study and analyze the global IGY Polyclonal Antibodies market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of IGY Polyclonal Antibodies market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global IGY Polyclonal Antibodies companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of IGY Polyclonal Antibodies submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of IGY Polyclonal Antibodies are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of IGY Polyclonal Antibodies market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.